Ongoing congressional oversight and Justice Department file releases have intensified scrutiny of Jeffrey Epstein’s network and the circumstances of his 2019 death, yet no U.S. government agency or court has altered the official suicide ruling. Multiple reviews, including a detailed 2026 examination of new documents and interviews, have reinforced evidence of prior suicide attempts and intent while finding no proof of homicide. State-level probes, such as New Mexico’s Truth Commission subpoenas, target non-prosecution decisions rather than the cause of death. With the market resolving on definitive confirmation by December 31, 2026, traders appear to price in limited near-term shifts from these investigations, consistent with historical patterns where official medical and inspector general findings have held despite public skepticism.